With talks of Medicare negotiation on the rise, Sue is concerned that more governmental control in the Medicare system will do more harm than good, putting politicians between patients and their doctors and impacting access and innovation.

But repealing a key patient protection in Medicare is not the only concern for Sue; having access to new medications and tools when they come to market is vital. Sue is worried that enacting government price-setting measures would impede her ability to access new medicines, as well as the biopharmaceutical industry’s ability to develop them.
Scientific innovation has made it easier for Sue to live with her disease, as it has for millions of Americans, and she is not willing to sacrifice that progress for so called “negotiation.” We should focus instead on solutions that can lower what patients pay out of pocket — without sacrificing access or innovation.

Sue feels strongly that price-setting proposals like H.R. 3 that could halt innovation and reduce her access to new medicines, alongside government interference in Medicare that could impact which medicines she can get, are the wrong approach. She believes that there is a better way to approach affordability that does not sacrifice what is most important to patients: continued development of new and effective treatments.  We must protect access to the treatments that have enabled patients like Sue to live healthier and more independent lives.

Take action now.